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Abstract
                Newer non-pharmacological therapies for heart failure are being evaluated for patients 
of congestive heart failure (CHF). Mechanical support with left ventricular assist devices and 
heart transplantation are reserved for the minority of patients who have severely decompensated 
heart failure. Despite these therapeutic advances, it is generally accepted that current therapies 
do not adequately address the clinical need of patients with heart failure, and additional 
strategies are being developed. Cardiac resynchronization therapy (CRT) is a new modality that 
involves synchronization of ventricular contraction and has shown a lot of promise in managing 
symptomatic patients of CHF who are on optimal medical therapy and have interventricular 
conduction delay (IVCD). It has improved exercise tolerance and NYHA functional class in 
such patients in sinus rhythm and a recent meta-analysis has also shown mortality benefits in 
CHF. Recently benefits of CRT have also been observed in CHF patients who do not have wide 
QRS complexes on electrocardiogram (EKG). It has also been shown to benefit drug refractory 
angina in CHF. Recent studies have also focused on the combined use of CRT and implantable 
cardioverter defibrillator (ICD) and it has shown encouraging results. Our aim in this descriptive 
review is to define practice guidelines and to improve clinicians' knowledge of the available 
published   clinical   evidence,   concentrating   on   few   randomized   controlled   trials.          
Introduction
            Approximately 30 percent of patients with cardiomyopathy have IVCD such as left or 
right bundle-branch block, leading to loss of coordination of ventricular contraction1,2. This 
dyssynchronous   pattern   of   ventricular   contraction   is   believed   to   contribute   to   the 
pathophysiology of heart failure, reducing the already diminished contractile reserve of the 
heart3. Specifically, dyssynchronous contraction exacerbates inefficient use of energy by the 
heart (a process termed mechanoenergetic-uncoupling4).  The finding of IVCD has been 
associated with clinical instability and an increased risk of death in patients with heart 
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failure5,6,7,8.
             Accordingly, the idea that cardiac-pacing technology might be used to restore the 
synchrony of ventricular contraction has been of theoretical interest for over a decade. Pacing 
modalities that utilize biventricular (BiV) or left ventricular (LV) stimulation to optimize cardiac 
pump   function   through   synchronization   of   ventricular   contraction   are   referred   to   as 
resynchronization or ventricular resynchronization therapies2. Resynchronization therapies can 
be present in a single device, in a device equipped with bradycardia pacing support, or 
incorporated into an ICD9.                                                                                             
CHF and IVCD                                                                                                       
            The most common causes for an IVCD in patients with heart failure are delayed left 
ventricular activation and left bundle branch block (LBBB). Impaired left ventricular function is 
also seen in otherwise normal subjects with isolated LBBB10. Approximately 20 to 30 percent of 
patients with symptomatic heart failure have an IVCD.2 In a study done by Farewell et al11 
patients with a hospital diagnosis of "heart failure" were investigated. These patients did not 
undergo cardiac catherterization. The criteria for inclusion were severe heart failure (NYHA 
Class III or IV), heart failure due to dilated cardiomyopathy, QRS duration > 120 ms, or the 
presence of LBBB or RBBB. Using these criteria, approximately 10 percent of an unselected 
group of heart failure patients who are admitted to a typical district general hospital in United 
Kingdom during a calendar year would be candidates for biventricular pacing. A recent study 
done by Erdogan et al12 estimated that biventricular pacing might be considered as an adjunct to 
standard heart failure therapy in 5-10 patients per year per 100,000 residents in industrial 
countries.
In Europe Resynchronization therapy is approved for symptomatic heart failure that occurs in 
the setting of IVCD or BBB. This approval was granted on the basis of several studies of acute 
resynchronization therapy and data compiled in approximately 150 patients receiving BiV or LV 
stimulation for three months as part of two controlled studies (InSync 13,14 and PATH-CHF15). 
In the United States, resynchronization therapy with or without an ICD is approved for patients 
with NYHA class III-IV heart failure on the basis of the chronic studies described below, which 
were   all   performed   with   a   control   group   randomly   assigned   to   no   resynchronization 
therapy16,17,18,19,20,21,22.  
            There is another setting in which resynchronization might be important. It is estimated 
that approximately 8 to 15 percent of patients with advanced heart failure have pacemakers 
implanted for symptomatic bradycardia. Such patients have an increased risk of mortality or 
urgent transplantation due to progressive pump dysfunction; in one series, the risk at one year 
was 49 versus 15 percent in patients without a pacemaker).23 This difference may be due in part 
to   the   dyssynchronous   contraction   caused   by   right   ventricular   (RV)   based   pacing.
            Whether such patients would derive long-term benefit from "upgrading" these devices to 
resynchronization therapies by the addition of a LV lead is currently under investigation. Initial 
data in patients with severe heart failure, prior atrio-ventricular (AV) junction ablation for rate 
control of AF, and chronic RV pacing has shown that there are significant benefits by upgrading 
from RV to BiV pacing.24                                                                                           
Effect  on   Contractile  Function                                                                           
             Hemodynamic data acquired in patients with heart failure and bundle branch block 
(BBB) during acute or chronic BiV or LV stimulation have consistently shown improvements in 
measures of contractile response, such as force of contraction, cardiac output, left ventricular 
ejection fraction (LVEF), and pulmonary artery pressure, when compared to normal sinus 
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rhythm or RV pacing25,26,27,28,29,30,31,32. CRT has been shown to decrease the functional mitral 
regurgitation in advanced systolic heart failure33,34. In contrast to other therapies that increase 
myocardial contractility, BiV and LV stimulation appear to modestly reduce myocardial energy 
demands and myocardial oxygen consumption3. The magnitude of acute systolic improvement 
by CRT is mainly due to resynchronization rather than due to change in myocyte function. An 
increased mechanical efficiency without increase in oxygen demand can be effective in drug 
refractory angina in CHF. A study done by Gasparini et al35 showed the beneficial effects of 
CRT, during a mean follow-up of 9 months, in increasing the angina threshold in severely 
symptomatic patients with CHF and coronary artery disease (CAD) not amenable to cardiac 
revascularization. This study suggested that CRT increases the ischemic threshold in CHF 
patients on the long term, by markedly reducing the incidence of drug refractory anginal 
episodes, and by increasing a previously profoundly reduced exercise capacity. In another series 
of 18 patients with dilated cardiomyopathy (DCM) and an IVCD, aortic and LV pressures, dp/dt, 
and pressure-volume measurements were obtained during stimulation at single RV endocardial 
sites, at single LV epicardial sites, or during BiV pacing36. There was an improvement in 
systolic pressures with LV free wall or BiV stimulation, primarily due to an improvement in 
systolic function; there was no benefit on diastolic filling pressure or relaxation and RV apical or 
septal stimulation did not produce any hemodynamic changes. The markers of sympathetic 
activation, such as serum norepinephrine and heart rate variability, often vary directly with the 
severity of heart failure, these markers have not predictably changed in patients in whom 
resynchronization therapy appears to improve contractile function37,38,39,40. The improvement 
in   mechanical   synchrony   appears   to   be   the   mechanism   for   reverse   remodeling41.  
Reverse   Remodeling                                                                                
            Based upon echocardiography, preliminary data from the MIRACLE trial16 suggested 
that BiV pacing is associated with reverse remodeling in patients with heart failure. BiV pacing 
produced an improvement in cardiac structure and function with a significant reduction in mitral 
regurgitation jet area and left ventricular mass, both signs of reverse remodeling42. Reverse 
remodeling was also observed in the CONTAK CD, PATH-CHF, and VIGOR CHF trials, in 
which BiV produced a significant reduction in left ventricular end-systolic and end-diastolic 
dimensions on echocardiography38,43. In the PATH-CHF trial, baseline left ventricular end-
diastolic volumes were significantly smaller in those who exhibited reverse remodeling with 
BiV pacing compared to those who did not have a reduction in left ventricular volume43.
Clinical   Trials                                                                                      
            There are a number of trials evaluating the role of resynchronization therapy in patients 
with heart failure due to systolic dysfunction. The usual inclusion criteria include symptomatic 
heart failure that is stable on medical therapy, New York Heart Association (NYHA) class II to 
IV, left ventricular ejection fraction (LVEF) <35 percent, QRS duration >120 to 140 ms, and, in 
some   trials,   an   indication   for   an   ICD.                                                            
MIRACLE   Trial                                                                                               
            In this trial16 453 patients with moderate-to-severe symptoms of heart failure associated 
with an LVEF of 35 percent or less and a QRS interval of 130 ms or more were studied. They 
were randomly assigned to a cardiac-resynchronization group (228 patients) or to a control 
group (225 patients) for six months, while conventional therapy for heart failure was maintained. 
Indian Pacing and Electrophysiology Journal (ISSN 0972-6292), 3(3): 129-142 (2006)Bhatia V, Bhatia R, Dhindsa S, Virk A, “Cardiac Resynchronization Therapy               132 
In Heart Failure: Recent Advances And New Insights” 
The primary end points were the NYHA functional class, quality of life, and the distance walked 
in   six-minutes.   As   compared   with   the   control   group,   patients   assigned   to   cardiac 
resynchronization experienced an improvement in the distance walked in six-minutes (+39 vs. 
+10 m, P=0.005), functional class (P<0.001), quality of life (–18.0 vs. –9.0 points, P= 0.001), 
time on the treadmill during exercise testing (+81 vs. +19 sec, P=0.001), and ejection fraction 
(+4.6 percent vs. –0.2 percent, P<0.001). In addition, fewer patients in the group assigned to 
cardiac resynchronization than control patients required hospitalization (8 percent vs. 15 
percent) or intravenous medications (7 percent vs. 15 percent) for the treatment of heart failure 
(P<0.05 for both comparisons). Implantation of the device was unsuccessful in 8 percent of 
patients and was complicated by refractory hypotension, bradycardia, or asystole in four patients 
(two of whom died) and by perforation of the coronary sinus requiring pericardiocentesis in two 
others.  
MUSTIC   Trial                                                                                        
             The MUSTIC (Multisite Stimulation in Cardiomyopathies) trial is a single-blind 
randomized, controlled crossover study involving 131 patients who were divided into two 
groups based upon their underlying rhythm17,18,19. Group one included 67 patients with NYHA 
class III heart failure, QRS duration >150 ms with stable sinus rhythm and no conventional 
indications for pacemaker therapy17. The patients were randomly assigned to BiV pacing or no 
BiV pacing for three months, after which the pacing modes were switched; a total of 48 patients 
completed both phases of the study (MUSTIC SR). Exercise tolerance, as measured by the six-
minute walk distance, increased by 23 percent after BiV pacing (399 versus 326 m, p<0.001). 
Other significant improvements included a 32 percent increase in quality of life, an 8 percent 
increase   in   peak   oxygen   consumption,   and   a   two-thirds   reduction   in   hospitalizations. 
Furthermore, BiV pacing was preferred by 85 percent of patients. At the end of the six-month 
crossover phase, the patients were programmed to the phase they preferred or, if there was no 
preference, according to the physician's judgment; almost all patients ended up with BiV pacing. 
The benefits with BiV pacing compared to baseline were maintained at 12 months19. Group two 
included 59 patients with heart failure and chronic atrial fibrillation (AF) with a wide QRS 
complex that required a permanent pacemaker because of a slow ventricular rate (MUSTIC AF). 
These patients were randomly assigned to either single site RV pacing or BiV pacing in the 
same fashion as in group one18,19. Only 37 patients completed the six-month crossover trial, 
which limits any conclusions that can be drawn18. Using an intention-to-treat analysis, there 
were no significant differences in exercise tolerance or peak oxygen consumption. In contrast, 
when only the 37 patients who completed the study were evaluated, biventricular pacing was 
associated with a significant increase in six-minute walking distance (9.3 percent, 32 meters) 
and peak oxygen consumption (13 percent, 1.7 mL/kg per min). At the end of the six-month 
crossover phase, 33 of 37 patients (89 percent) preferred BiV pacing. Among 33 patients 
followed at one year, significant improvements persisted in both six-minute walking distance 
and   peak   oxygen   consumption.                                                                        
CRT and Implantable Cardioverter Defibrillator (ICD) Therapy                                    
            Recently there has been some trials evaluating the combined use of CRT and ICD in 
patients   of   heart   failure.                                                                    
I.     InSync trial44 demonstrated the efficacy and safety of implanting a combined device in 362 
patients with class III and IV heart failure who also required an ICD. Patients were randomly 
assigned to have BiV pacing turned on or off; the ICD was active in all patients. InSync ICD 
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Italian Registry45 studied InSync ICD model 7272, a dual chamber ICD combined with CRT. In 
this registry, CRT combined with ICD implantation has been feasible with few device or left 
pacing lead related complications and this was found to be concordant with previous reports9. 
The clinical benefits match those obtained in recipients of biventricular pacemakers, both in 
LVEF   and   NYHA   functional   class16.                                                        
II.     VENTAK CHF/CONTAK CD22 enrolled 581 patients with heart failure, most of whom 
had an ischemic cardiomyopathy, who also had an indication for an ICD. The majority of 
patients were male, had NYHA class II to IV heart failure, and a QRS duration >120 ms. The 
study utilized an ICD system designed to provide BiV pacing. All patients had an ICD and either 
BiV   pacing   or   no   pacing,   each   for   six   months.                                          
III.     The COMPANION trial46 is a study of resynchronization therapy with and without an 
ICD in patients with NYHA class III-IV heart failure who had a hospitalization for heart failure 
within the year prior to enrollment. Nearly half of all patients enrolled had a non-ischemic 
etiology  of   heart  failure.   Patients  were  randomly  assigned  to  optimal  medical  therapy, 
resynchronization alone, or resynchronization with an ICD. The trial was discontinued in 
November 2002 due to a significant benefit in the combined end point of total hospitalizations 
and mortality among  the  device treated patients.                                                     
Effects Of CRT and ICD Therapy on Arrhythmic Burden                               
            Preliminary reports suggest that BiV pacing has an anti-arrhythmic effect43,47. The anti-
arrhythmic effect has been attributed to improved hemodynamics. A low mean number of 
ventricular arrhythmic episodes were observed in the whole population and in the patients 
without Class I indications in InSync Italian registry45. It was found that the patients without 
standard ICD indications sustained serious arrhythmic events, confirming their high risk of 
death.
Pacing   Sites                                                                                              
             Short-term studies have suggested that the lateral wall is a preferred site of LV 
stimulation to achieve effective CRT3,25. However, this choice may be limited by technical 
difficulties like high capture threshold from the presence of scar or fibrosis, particularly in 
patients with CAD, determining high LV pacing threshold, unfavorable coronary venous 
anatomy with narrow and tortuous coronary sinus tributary (CST), phrenic nerve stimulation or 
pacing lead instability. Gasparini et al48 conducted a study to evaluate the effects of different 
pacing sites in patients treated with CRT. The data from this study revealed that, during long 
term  follow-up,  the  most important  clinical and  echocardiographic  parameters improved 
significantly in the patients, independently of the stimulation site. This was the case when 
considering each CST separately, or when dividing patients between “lateral” and “septal” sites, 
in the entire population and in the subgroups of patients without CAD. Hence in the presence of 
major technical difficulties preventing stimulation of the lateral LV, alternative-pacing sites, 
particularly the basal anterior LV wall, may be suitable to offer effective CRT to these patients. 
Tissue Doppler echocardiography has also been used to determine the optimal pacing site for 
BiV pacing47 and to document an improvement in LV function, manifest by an increase in LV 
and interventricular synchrony, a shortened isovolumic contraction time, and an increased 
diastolic   filling   time41,50.                                                                    
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QRS Duration And Dyssynchrony                                                                                     
             Wide QRS duration, possibly with LBBB, has been proposed as an independent 
predictor of total mortality in CHF patients51,52,53. In addition it has been considered a key 
criteria for selecting CHF patients for CRT, as wide QRS has been suggested to be associated 
with marked RV to LV and intra-LV dyssynchrony10,25,54. However, the correlation between 
the QRS width and regional electromechanical LV dyssynchrony has not been completely 
clarified47,55,56 and a high prevalence of left ventricular systolic and diastolic asynchrony has 
been found in patients with congestive heart failure and normal QRS duration57. Hence for a 
given QRS width there is a considerable scatter in response to CRT responsive patients with 
narrow complexes and less responsive ones with wide complexes exist 32. A study was done by 
Gasparini et al58 to assess in a large cohort of patients the role of baseline QRS width (<150 / 
>150 ms) on clinical and echocardiographic parameters, hospitalization rates, and survival after 
CRT. In this study 158 CHF patients (121 men, mean age 65 years, mean LVEF 0.29, mean 
QRS width 174 ms) underwent successful BiV implantation and were then followed for a mean 
time of 11.2 months. According to the basal QRS duration, patients were divided in two groups 
with wide QRS group (>150 ms, 128 patients, 81 percent) and the narrow QRS (<10 ms, 30 
patients, 19 percent).        
In the wide QRS group, following results were noted: 
1. LVEF improved from 20 percent to 39 percent (P < 0.0001)
2. Six–minute walk test from 311 to 463 m (P<0.0001)
3. NYHA Class III-IV patients decreased from 86 percent to 8 percent (P<0.0001).
In the narrow QRS group, following were the results:
1. LVEF improved from 30 percent to 38 percent (P<0.0001).
2. Six-minute walk test 370 to 506 m (P<0.0001).
4. NYHA Class III-IV patients decreased from 60 percent to zero percent (P<0.0001). 
             The data showed that in wide and narrow QRS patients, BiV pacing significantly 
improved   clinical   parameters   (NYHA   lass,   six-minute   walk   test,   quality   of   life,   and 
hospitalization rate) and main echocardiographic indicators. Furthermore, narrow QRS patients 
had a better survival rate, rapidly regained left ventricular function, and only a few patients 
remained in a higher NYHA class during follow-up. These patients should not be excluded "a 
priori"   from   CRT.                                                                                    
            This study highlights the important point at what level a QRS has to be considered "wide 
enough" to be proposed to benefit from CRT. For example this was >150 ms for the MUSTIC 
study17, >130 ms in the MIRACLE study16, and >120 ms in Comparison of medical therapy, 
pacing, and defibrillation in chronic heart failure (COMPANION) trial46. It is evident from 
these differences in opinion that there is still no consensus on just how "wide" QRS should be 
for an efficacious CRT. Moreover the duration of QRS alone no longer seems to be defining 
parameter for patients with either inter-or-intraventricular dyssynchrony, given that recent 
studies have shown that even patients with a QRS<150 ms or without LBBB can suffer from 
significant dyssynchrony53,54.                                                                                         
Are There Any New Markers of Asynchrony?                                           
            The results of the recent investigations have prompted a reappraisal of the apparent 
correlation between conduction disorders and cardiac dyssynchronization. In a tissue Doppler 
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study of 104 patients with BBB, Garrigue et al56 observed that 35 percent of patients with 
LBBB had no interventricular dyssynchronization, and 20 percent had no left ventricular 
dyssynchronization. Despite fulfilling the "classic" criteria of wide QRS and LBBB, these 
patients are hardly candidates for CRT. Conversely, a sizable number of patients with right 
bundle branch block (RBBB) may present with mechanical anomalies, which may be corrected 
by CRT. Therefore, new markers of asynchrony are desirable, more directly related to cardiac 
mechanical function than the EKG. Among several methods available, angioscintigraphy with 
phase   analysis   of   the   contraction   isochrones   was   the   first,   though   its   cumbersome 
implementation, high cost, and limited availability in routine clinical practice have prevented its 
widespread   application59,60.                                                                              
            A recent study done by Cazeau S et al61 explored the value of an echocardiographic 
model to identify cardiac electromechanical dyssynchrony parameters (EDP) in candidates for 
CRT and their potential correction after implantation. The study included 66 CRT recipients of 
CRT NYHA functional class III or IV who had one or more AV, interventricular or intra-
ventricular dyssynchrony criteria. An immediate improvement was observed in 85 percent of the 
population with partial or total correction of their EDP. However the modification in EDP 
differed considerably between recipients of de novo CRT systems and patients with previously 
implanted standard pacing systems upgraded with the implantation of a left ventricular lead. 
EDP measurements appear to identify candidates for CRT and to confirm the success of system 
implantation. This is the first report of a selection of candidates for CRT based on mechanical 
instead of electrical criteria. An overlap certainly exists between patients presenting with a wide 
QRS and patients with disorders of cardiac synchronization. However the echocardiographic 
method, which distinguishes three different types of synchronization offers a finer analysis of 
the anomalies amenable to resynchronization.                                                           
Etiology   of   CHF   and   CRT                                                                  
            The mechanisms of CHF in patients with DCM are complex and multiple. A study done 
by Gasparini et al61 examined the importance of underlying cardiac pathology on the outcome of 
CRT, hypothesizing that myocardial infarction scar and the non-contractile segment represent 
limitations to the ability to resynchronize cardiac contraction in patients with CHF associated 
with DCM. The results of this study showed that the functional capacity improved significantly 
during CRT in CAD and non-CAD patients. LVEF and NYHA class in non-CAD patience 
showed a significantly greater improvement. However, changes in quality-of-life were similar in 
both groups. The mechanisms of slow myocardial conduction associated with asynergic 
contraction in patients with DCM vary with the underlying pathology5,62,63. In patients with 
DCM not due to CAD, ventricular asynergy may be associated with interventricular or intra-
ventricular conduction delays. Interventricular asynergy is most often associated with LBBB. A 
progressive   remodeling   of   myocardial   collagen   matrix   well   documented   in   familial 
cardiomyopathies may impair intraventricular conduction. Disruption of collagen network, by 
altering the cellular architecture, impairs intraventricular conduction and the coordinated 
mechanical response of the ventricles. The consequences are QRS prolongation and waste of 
mechanical work. In patients with CAD, beside ventricular remodeling, ventricular asynergy 
may be associated with segmental wall- motion abnormalities as result of myocardial infarction 
scars, or of ischemic non-contractile segments. Segmental wall motion abnormalities affect 
intraventricular conduction and the coordinated mechanical response of the ventricles. CRT may 
correct conduction delay in remodeled dilated myocardial segments, but has no effect on 
extensive myocardial scars or ischemic segments. CRT can only recruit and coordinate a 
fraction of the myocardial mass to increase ventricular mechanical work in patients with CAD. 
Although significant benefits were observed in both groups after CRT, myocardial infarction 
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scars limit the mechanical benefits of QRS narrowing and resynchronization. Hence the benefits 
of CRT should not be denied to patients with severe CHF on the basis of underlying cardiac 
pathology including patients with severe LV dysfunction associated with CAD and wide QRS64.
Pacing   in   AF                                                                                       
            Paroxysmal or persistent AF occurs in up to 30 percent of patients with HF65. Rate 
control can be achieved with pharmacological therapy. In patients refractory to such therapies 
these objectives can be achieved with radiofrequency ablation of the AV node and pacemaker 
therapy with traditional RV-based pacemakers. Initial data regarding "upgrading" from RV to 
BiV pacing using an LV lead to achieve cardiac resynchronization in heart failure patients with 
chronic AF who have undergone radiofrequency AV nodal ablation followed by standard RV 
pacing is promising.24                                                                                                                 
Recommendations
            BiV pacing is an effective approach to the therapy of patients with heart failure and 
IVCD and studies suggest that BiV pacing can improve exercise tolerance and NYHA functional 
class in such patients in sinus rhythm. A meta-analysis was done by Bradley et al66 of the 
available studies to determine the effect of CRT on mortality in CHF. 11 reports of 4 
randomized trials with 1634 total patients were included in this meta-analysis. It was found that 
cardiac resynchronization reduces mortality from progressive heart failure in patients with 
symptomatic left ventricular dysfunction. This finding suggests that cardiac resynchronization 
may have a substantial impact on the most common mechanism of death among patients with 
advanced heart failure. Cardiac resynchronization also reduces heart failure hospitalization and 
shows a trend toward reducing all-cause mortality.                                                                         
            More data on effect of CRT on mortality in CHF is still awaited. Although suggestive, 
the data are insufficient to prove efficacy in patients in AF18. As a result of the MIRACLE trial, 
the FDA has approved BiV pacing as a treatment for moderate to severe heart failure. Potential 
concerns include the small risk of serious complications during implantation as noted in 
MIRACLE16 and lack of data concerning the long-term effects of cardiac resynchronization as 
noted by the 2001 Task Force of the ACC/AHA67.                                                                 
            At present, it seems reasonable to consider BiV pacing in patients with a low LVEF and 
prolonged QRS duration who remain symptomatic (NYHA class III or IV HF) despite optimal 
medical   therapy68.   The   2002   task   force   of   the   ACC/AHA/NASPE   gave   a   class   IIa 
recommendation (weight of evidence in favor of efficacy) to BiV pacing in medically refractory, 
symptomatic NYHA class III or IV patients with idiopathic dilated or ischemic cardiomyopathy, 
prolonged QRS interval (130 ms), LV end-diastolic diameter greater than or equal to 55 mm and 
ejection fraction less than or equal to 30 percent.                                                                     
            It is not known if these devices should routinely incorporate a defibrillator. The MADIT 
II trial showed a significant survival benefit from ICD placement in patients who have had a 
previous myocardial infarction and have an LVEF 30 percent69. Combination therapy with an 
ICD and BiV might therefore be beneficial in such patients who have QRS prolongation.
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